StockNews.AI

Sanofi: Information concerning the total number of voting rights and shares - December 2025

StockNews.AI • 7 hours

SNY
Medium Materiality5/10

Information

Information concerning the total number of voting rights and shares, provided pursuant to article L....

Original source

AI Summary

As of December 2025, Sanofi's registered capital is €2.4 billion, with 1.22 billion issued shares. This capital and voting rights structure may influence institutional investor actions and overall stock liquidity.

Sentiment Rationale

Despite the informative nature of the capital structure and voting rights, there is no immediate catalyst for price movements. Past similar announcements have had a muted effect on stock prices.

Trading Thesis

Investors should watch for potential liquidity changes affecting SNY stock in the near term.

Market-Moving

  • The total number of shares can impact stock liquidity.
  • Changes in voting rights may alter investor sentiment toward SNY.
  • New regulations could affect Sanofi's capital structure and share value.
  • Treasury shares influence voting dynamics, affecting strategic decisions.

Key Facts

  • Sanofi has €2.4 billion registered capital as of December 2025.
  • Total issued shares stand at 1.22 billion, affecting market liquidity.
  • Real voting rights number 1.34 billion, significant for investor influence.
  • Theoretical voting rights, including treasury shares, are 1.35 billion.
  • Information accessible via Sanofi's investor relations website.

Companies Mentioned

  • Sanofi (SNY): SNY's capital structure may influence investor engagement and stock liquidity.

Corporate Developments

This falls under Corporate Developments as it discusses capital and voting rights aspects critical for corporate governance and shareholder influence, vital for potential investors to understand.

Sanofi Announces Updated Voting Rights and Share Information for December 2025

Sanofi (SNY), a leading global biopharmaceutical company, has released its latest data on the total number of voting rights and shares. This disclosure is mandated by article L. 233-8 II of the French Commercial Code and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers, highlighting the company's commitment to transparency in its operations. The update covers key figures as of December 31, 2025.

Key Financial Figures

On December 31, 2025, Sanofi reported the following data regarding its issued shares and voting rights:

  • Total number of issued shares: 1,219,502,152
  • Number of real voting rights (excluding treasury shares): 1,341,770,035
  • Theoretical number of voting rights (including treasury shares): 1,353,630,675

This data is in accordance with Article 223-11 of the aforementioned regulation standards.

Company Overview

Sanofi A.S., with a registered office located at 46, avenue de la Grande Armée, 75017 Paris, France, holds a registered share capital of €2,438,854,192. The company is registered under number 395 030 844 in the Paris Commercial and Companies Registry.

As a major player in the pharmaceutical industry, Sanofi focuses on developing innovative treatments and vaccines, thereby enhancing the quality of care for patients worldwide.

Accessing Additional Information

Investors and stakeholders can find this information and more on Sanofi's official website under the section entitled Regulated Information in France. For detailed insights, visit: Sanofi Voting Rights and Shares Overview.

Related News